A61P 35 - Antineoplastic agents

Patents for A61P 35 - Antineoplastic agents (221,099)
10/2004
10/14/2004	US20040202736 Method of ameliorating side-effects of SERMs
10/14/2004	US20040202676 using aggregating, delipidating or oxidating agents or compounds enabling the release of lipids from the particles and their heterogeneous aggregation, wherein aggregates with particle sizes of between 30 and 500 nm are subsequently selected by means of a molecular exclusion process
10/14/2004	US20040202663 Therapy for primary and metastatic cancers
10/14/2004	US20040202657 Humanized anti-CD3 specific antibodies
10/14/2004	US20040202656 Use of binding partners for 5-HT5 receptors for the treatment of neurodegenerative and neuropsychiatric disorders
10/14/2004	US20040202654 gp100-derived polypeptides that contain both a helper T-cell epitope and a cytotoxic T-cell epitope used to induce antitumor responses in melanoma patients
10/14/2004	US20040202651 Uses of anti-insulin-like growth factor 1 receptor antibodies
10/14/2004	US20040202647 T cell line specific for a nitrotyrosine-containing compound; antibody specific for a self-antigen comprising a tyrosine to nitrotyrosine conversion; prevention and treatment of autoimmune diseases, infectious diseases and cancer through the recognition of compounds containing nitrated tyrosine residues
10/14/2004	US20040202641 Recombinant super-compound interferon
10/14/2004	DE10315024A1 Wirkstoffkombination aus ω3-fettsäurehaltigen Ölen mit isoprenoidhaltigen Pflanzenextrakten und deren Verwendung Active ingredient combination of ω3-fatty acid-containing oils with isoprenoidhaltigen plant extracts and their use
10/14/2004	DE10295684T9 Verfahren zum spezifischen Hemmen von Histon-Deacetylase-4 Method for the specific inhibition of histone deacetylase 4
10/14/2004	CA2523126A1 Thiazoles useful as inhibitors of protein kinases
10/14/2004	CA2523125A1 Thiazoles useful as inhibitors of protein kinases
10/14/2004	CA2521123A1 Composition and method for supporting cancer treatments
10/14/2004	CA2521056A1 Hydrazone derivative
10/14/2004	CA2521055A1 Methyl-.beta.-orcinolcarboxylate from lichen (everniastrum cirrhatum) for use for the treatment of fungal infections and cancer
10/14/2004	CA2520997A1 Salts of tricyclic inhibitors of poly(adp-ribose) polymerases
10/14/2004	CA2520936A1 An antibody fragment capable of modulating multidrug resistance and compositions and kits and methods using same
10/14/2004	CA2520932A1 Dosage forms comprising ag013736
10/14/2004	CA2520406A1 Cxcr4 antagonists and methods of their use
10/14/2004	CA2520377A1 Migrastatin analog compositions and uses thereof
10/14/2004	CA2520372A1 Stq-peptides
10/14/2004	CA2519301A1 Oxime derivatives and their use as pharmaceutically active agents
10/13/2004	EP1466988A2 Genes and gene expression products that are differentially regulated in prostate cancer
10/13/2004	EP1466902A1 Androgen receptor antagonists
10/13/2004	EP1466891A1 Carboxylic acid derivative
10/13/2004	EP1466628A1 DHA-pharmaceutical agent conjugates
10/13/2004	EP1466627A1 Polyglutamate camptothecin conjugates
10/13/2004	EP1466616A2 Use of CASB616 polypeptides and polynucleotides for cancer treatment
10/13/2004	EP1466615A1 Pharmaceutical composition
10/13/2004	EP1466614A1 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon
10/13/2004	EP1466608A1 Herbal composition comprising Angelica gigantis, Cnidium officinale and Paeonia japonica
10/13/2004	EP1466607A1 Compositions for the treatment of primary and metastatic neoplastic diseases using arsenic compounds in combination with all-trans retinoic acid
10/13/2004	EP1466604A1 Isoquinoline derivatives, process for their preparation and use thereof in the treatment of melatoninergic system problems
10/13/2004	EP1466602A1 Organ fibrosis inhibitors
10/13/2004	EP1466600A1 Ready-to-use oxaliplatin solutions
10/13/2004	EP1466599A1 Concentrated solution of oxaliplatinum
10/13/2004	EP1466596A1 Novel microsphere and method for production thereof
10/13/2004	EP1466177A2 Discovery of therapeutic products
10/13/2004	EP1466175A2 SPHKs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/13/2004	EP1466174A2 Mutations in the bcr-abl tyrosine kinase associated with resistance to sti-571
10/13/2004	EP1465997A2 Use of biomolecular targets in the treatment and visualization of tumors
10/13/2004	EP1465996A2 Raf/ras binding compounds
10/13/2004	EP1465995A1 Bispecific antisense olignucleotides that inhibit igfbp-2 and igfbp-5 and methods of using same
10/13/2004	EP1465925A2 Antibodies that immunospecifically bind to trail receptors
10/13/2004	EP1465924A2 Modulators of notch ic protease activity for use in immunotherapy
10/13/2004	EP1465920A2 Mammalian simp protein, gene sequence and uses thereof in cancer therapy
10/13/2004	EP1465912A2 Novel chimeric tnf ligands
10/13/2004	EP1465906A1 Compositions and methods relating to endometrial specific genes and proteins
10/13/2004	EP1465900A1 Rho-kinase inhibitors
10/13/2004	EP1465899A1 Trioxane derivatives
10/13/2004	EP1465898A1 Biocidal compounds and their preparation
10/13/2004	EP1465896A2 Mitotic kinesin inhibitors
10/13/2004	EP1465891A2 Inhibitors of dipeptidyl peptidase iv
10/13/2004	EP1465889A1 Chemokine receptor binding heterocyclic compounds with enhanced efficacy
10/13/2004	EP1465887A1 Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical compositions containing the novel forms and methods for treating nausea using them
10/13/2004	EP1465886A1 Bipyridinyl derivatives as a highly selective cyclooxygenase-2 inhibitor
10/13/2004	EP1465880A1 5-sulphanyl-4h-1,2,4-triazole derivatives and their use as medicine
10/13/2004	EP1465876A1 Long chain fatty alcohol substituents in antineoplastic agents
10/13/2004	EP1465869A1 Modulators of lxr
10/13/2004	EP1465864A1 Inhibitors of factor xa and other serine proteases involved in the coagulation cascade
10/13/2004	EP1465852A1 Synthesis of combretastatin a-2 prodrugs
10/13/2004	EP1465666A2 Multicomponent assemblies having enhanced binding properties for diagnosis and therapy
10/13/2004	EP1465661A1 Cancer treatment
10/13/2004	EP1465660A2 Methods and compositions for modulating regulation of the cytotoxic lymphocyte response by macrophage migration inhibitory factor
10/13/2004	EP1465654A2 Plasmid mediated suplementation for treating chronically ill subjects
10/13/2004	EP1465651A1 Use of c-jun or c-jun activating agents such as uv or c-jun n-terminal kinases (junks) for treating cancer
10/13/2004	EP1465649A2 Methods and compositions for derepression of iap-inhibited caspase
10/13/2004	EP1465645A1 A novel herbal chemical composition for the treatment of cancer
10/13/2004	EP1465642A1 Protection against the neurotoxicity of oxaliplatin through the administration of calcium and magnesium
10/13/2004	EP1465633A1 Quinazolinone compounds in combined modalities for improved cancer treatment
10/13/2004	EP1465632A1 Quinazoline derivatives for the treatment of abnormal cell growth
10/13/2004	EP1465631A2 Pyrimidine a2b selective antagonist compounds, their synthesis and use
10/13/2004	EP1465627A1 DOSING REGIMEN FOR PPAR−GAMMA ACTIVATORS
10/13/2004	EP1465625A2 Solubilized topoisomerase poisons
10/13/2004	EP1465619A1 Suppression of cartilage degradation via the estrogen receptor
10/13/2004	EP1465617A1 Process for affecting neurologic progression
10/13/2004	EP1465614A2 A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
10/13/2004	EP1465599A1 Liposome composition for delivery of nucleic acid
10/13/2004	EP1465596A1 Polymeric gel system for the controlled delivery of codrugs
10/13/2004	EP1397137A4 Hydantion derivatives as inhibitors of matrix metalloproteinases
10/13/2004	EP1289515B1 Pharmaceutical composition containing at least a polymer associated or conjugated with at least a phenylalkylcarboxylic acid salt, conjugate polymers and uses thereof
10/13/2004	EP1280820B1 Anti-inflammatory compounds and uses thereof
10/13/2004	EP1268472B1 3-aminopyrazole inhibitors of cyclin dependent kinases
10/13/2004	EP1250095B1 Versatile hydrophilic dyes
10/13/2004	EP1202735B1 The use of a benzimidazole in the preparation of a medicament for the prevention of cancer.
10/13/2004	EP1185529B1 Pyrazolobenzodiazepines as cdk2 inhibitors
10/13/2004	EP1169038A4 Cyclic protein tyrosine kinase inhibitors
10/13/2004	EP1165069B1 Antitumour synergistic composition
10/13/2004	EP1131340B1 Hexapeptide with the stabilized disulfide bond and derivatives thereof regulating metabolism, proliferation, differentiation and apoptosis
10/13/2004	EP1093383B1 Drug delivery system comprising a homeobox peptide and a cytotoxic or antineoplastic drug
10/13/2004	EP1087786B1 Methods and materials for the treatment of prostatic carcinoma
10/13/2004	EP1086086B1 Imidazolyl derivatives and their use as somatostatin receptor ligands
10/13/2004	EP0921821B1 2-methoxyestradiol-induced apoptosis in cancer cells
10/13/2004	EP0719147B1 Gene therapy for solid tumors, papillomas and warts
10/13/2004	EP0637933B1 Method for treating organs and tissues
10/13/2004	EP0595838B1 Tumor rejection antigen precursors, tumor rejection antigens and uses thereof
10/13/2004	CN1537164A Compositions and methods for therapy and diagnosis of Her-2/neu associated malignancies
10/13/2004	CN1537161A Antigen presenting cells, method for their preparation and their use for cancer vaccines
10/13/2004	CN1537115A C2,5'-disubstituted and N6, C2, 5' trisubstituted adenosine derivatives and their different uses

1 ... 1366 1367 1368 1369 1370 1371 1372 1373 1374 1375 1376 1377 1378 1379 1380 1381 1382 1383 1384 1385 1386 ... 2211